N-Terminal Sequencing

Edman Degradation Sequencing Service

The gold-standard chemical method for N-terminal protein sequencing. Direct, unambiguous residue-by-residue identification by automated Edman degradation chemistry — trusted for biopharmaceutical QC, recombinant protein validation, and synthetic peptide confirmation.

PITC Chemistry PTH-Amino Acid Detection Up to 70 Residues Regulatory Identity Testing

Service Scope

Direct N-terminal sequence determination by automated Edman degradation

science

Method

Stepwise chemical degradation with PTH-amino acid identification.

Read Length

Up to 70 residues from the N-terminus.

Leu/Ile

Chromatographic separation of isobaric residues.

Platform

Shimadzu PPSQ automated protein sequencer.

Residue read length achievable.

Leu/Ile

Isobaric residue resolution.

ICH Q6B

Regulatory identity testing.

Service Details

Workflow

Platform

Deliverables

Case Study

Request a Quote

What Is Edman Degradation Sequencing?

Edman degradation, developed by Pehr Edman in 1950, is the classical chemical method for determining the N-terminal amino acid sequence of proteins and peptides. The method sequentially removes and identifies one amino acid residue at a time from the N-terminus — without breaking peptide bonds between other residues — yielding an unambiguous, residue-by-residue sequence read.

Each cycle involves three core chemical steps: (1) coupling of phenyl isothiocyanate (PITC) to the free N-terminal α-amino group under alkaline conditions; (2) acid-catalyzed cleavage of the N-terminal residue as a thiazolinone derivative; and (3) conversion to the more stable phenylthiohydantoin (PTH)-amino acid, which is then identified by online reversed-phase HPLC against known standards.

With the rise of mass spectrometry, Edman degradation is no longer the only option for protein sequencing — but it remains the gold standard for N-terminal identity confirmation where a direct, unambiguous chemical read is required. Edman sequencing continues to be specified by regulatory guidelines (ICH Q6B) for biopharmaceutical identity testing, and it provides capabilities — such as resolving leucine from isoleucine at the N-terminus — that remain challenging even for modern LC-MS/MS workflows. The method requires a free (unblocked) N-terminal α-amino group; proteins with acetylated, pyroglutamylated, or formylated N-termini are not directly accessible to Edman chemistry. For blocked N-termini, LC-MS/MS-based N-terminal sequencing provides a complementary solution.

Scientific illustration of the Edman degradation reaction cycle — PITC coupling to N-terminal amine, acid-catalyzed cleavage of PTH-amino acid derivative, and HPLC chromatogram identifying the released residue.

Edman Degradation vs. Mass Spectrometry for N-Terminal Sequencing

Dimension	Edman Degradation	Mass Spectrometry (LC-MS/MS)
Read Model	Direct, cycle-by-cycle chemical identification (PTH-amino acid detection by HPLC)	Inferred from fragmentation spectra and database/algorithmic interpretation
Leu/Ile Resolution at N-Terminus	Resolved by HPLC — PTH-Leu and PTH-Ile are chromatographically separable	Requires specialized fragmentation — EThcD, UVPD, or ion mobility; context-dependent
Sample Form	Purified protein in solution or PVDF-blotted band; free N-terminus required	Digested peptides or intact/top-down; handles mixtures and blocked termini
Typical Read Span	30–40 residues standard; up to 70 with optimized loading	Full sequence coverage via peptide maps; terminal coverage varies
Blocked N-Termini	Not accessible — de-blocking required before sequencing	Accessible — no de-blocking chemistry needed
Strengths	Definitive terminal identity; orthogonal to MS; ICH Q6B-aligned; resolves Leu/Ile	Throughput; PTM landscape; sensitivity; compatible with complex mixtures
Regulatory Acceptance	Highly accepted — explicit in ICH Q6B identity testing	Highly accepted — peptide mapping + MS for structural characterization

Edman degradation and LC-MS/MS are orthogonal, complementary methods. For comprehensive terminal characterization — including blocked N-termini — we recommend combining Edman sequencing with MS-based N-terminal analysis for the most complete terminal characterization.

Our Edman Degradation Sequencing Services

Automated Edman degradation sequencing on the Shimadzu PPSQ platform, with applications spanning biopharmaceutical QC, recombinant protein validation, and peptide characterization.

science

N-Terminal Sequencing

Direct N-terminal sequence determination by automated Edman degradation on the Shimadzu PPSQ platform. Standard read length of 30 residues, expandable to 60–70 with optimized protein loading. PTH-amino acid identification by online HPLC with UV detection against calibration standards.

PPSQ System PTH-HPLC

verified

Recombinant Protein Validation

Confirm the N-terminal sequence of recombinant proteins after expression and purification. Verify correct translation start site, signal peptide cleavage, and N-terminal methionine processing. Essential for cell line development and production consistency.

QC & Validation

description

Synthetic Peptide QC

Verify the correct sequence of synthetic peptides by N-terminal Edman sequencing. Confirm that the synthesis product matches the intended sequence before use in biological assays, antibody production, or as reference standards.

Synthesis Verification

cut

Degradation & Cleavage Analysis

Identify the N-terminus of protein fragments generated by proteolysis or chemical degradation. Determine exact cleavage sites by sequencing the N-terminus of each fragment — critical for understanding protein stability and degradation pathways.

Cleavage Mapping

How Edman Degradation Sequencing Works

Each Edman cycle removes and identifies one N-terminal amino acid. The process repeats automatically on the Shimadzu PPSQ sequencer until the desired read length is reached.

PITC Coupling

Under alkaline conditions, phenyl isothiocyanate (PITC) reacts selectively with the free α-amino group at the N-terminus of the protein, forming a phenylthiocarbamyl (PTC) derivative.

Acid Cleavage

Treatment with anhydrous acid (typically trifluoroacetic acid) selectively cleaves the N-terminal peptide bond, releasing the terminal residue as an anilinothiazolinone (ATZ) derivative while leaving the rest of the protein intact.

PTH Conversion

The unstable ATZ derivative is converted to the more stable phenylthiohydantoin (PTH)-amino acid in aqueous acid, ready for chromatographic identification.

HPLC Identification

The PTH-amino acid is injected onto a reversed-phase C18 column and identified by retention time against calibration standards. Each amino acid produces a characteristic peak position.

Cycle & Report

The shortened protein enters the next cycle. After 30–70 cycles, the full N-terminal sequence is assembled from the chromatographic data, with each cycle reporting the identity and yield of the released PTH-amino acid.

Why Edman Remains the Gold Standard

difference

Leu/Ile Differentiation

PTH-leucine and PTH-isoleucine are chromatographically separable by HPLC — a capability that mass spectrometry cannot easily replicate without advanced fragmentation techniques (EThcD, UVPD) or ion mobility separation. For N-terminal identity testing, Edman provides a direct, unambiguous answer to a question MS often leaves unresolved.

gavel

Regulatory Alignment

ICH Q6B specifies N-terminal sequencing as an identity test for biotechnological/biological products. Edman degradation's direct chemical read provides the unambiguous terminal evidence that regulators expect in dossiers — orthogonal to MS peptide mapping, strengthening the overall characterization package.

layers

Orthogonal Validation

Independent, non-overlapping methods are the foundation of strong analytical characterization. Edman sequencing provides a chemically distinct readout from MS — cross-validating terminal identity and catching errors that either method alone might miss. For biosimilar comparability exercises, this orthogonal evidence is particularly valued by reviewers.

Dealing with Blocked N-Termini

Many naturally occurring and recombinant proteins have chemically modified N-termini that block Edman chemistry. We offer validated de-blocking strategies to recover sequenceable N-termini.

Blocking Modification	Common Occurrence	De-Blocking Strategy	Success Rate
N-Acetylation	~80% of eukaryotic cytosolic proteins	Chemical de-acetylation (TFA treatment) or enzymatic de-acetylase	Moderate — depends on accessibility
Pyroglutamate (pGlu)	mAb light/heavy chains; cyclized N-terminal Gln/Glu	Pyroglutamate aminopeptidase (PGAP) enzymatic removal	High — well-established for antibodies
N-Formylation	Prokaryotic (E. coli) recombinant proteins	Mild acid hydrolysis or peptide deformylase	Moderate to high
PEGylation	PEGylated protein therapeutics	Not de-blockable by Edman chemistry	Use LC-MS/MS instead

When de-blocking is not feasible or the modification type is unknown, LC-MS/MS-based N-terminal sequencing is the recommended alternative — it works directly with blocked, modified, PEGylated, and glycosylated N-termini.

Edman Degradation Sequencing Platform

Close-up of Shimadzu PPSQ automated protein sequencer performing Edman degradation, with HPLC system for PTH-amino acid detection.

biotech

Shimadzu PPSQ-51A/53A Sequencer

Latest-generation automated protein sequencer. Gas-phase Edman chemistry with integrated PTH-amino acid HPLC analysis. FDA 21 CFR Part 11 compatible software for regulated environments.

water_drop

Online PTH-HPLC Detection

Reversed-phase C18 HPLC column with UV detection at 269 nm. PTH-amino acid standards calibrated daily for retention time matching. Chromatographic separation of isobaric Leu/Ile residues.

receipt_long

Data Analysis Software

Automated peak integration, retention time matching, and amino acid assignment. Cycle-by-cycle yield monitoring to track sequencing efficiency and detect premature termination or background accumulation.

checklist

Regulatory Compliance

PPSQ software supports FDA 21 CFR Part 11 requirements — audit trails, electronic signatures, and secure data management. Chromatograms and sequence assignments are fully traceable for regulatory submissions.

Instrument Specifications

Parameter	Specification
Sequencer Model	Shimadzu PPSQ-51A/53A
Chemistry	Gas-phase Edman degradation with PITC coupling
Detection	Online reversed-phase HPLC with UV (269 nm) — PTH-amino acid identification
Standard Read Length	30 residues; up to 70 with optimized protein loading
Sensitivity	Low picomole-level detection of PTH-amino acids
Sample Compatibility	Solution-phase proteins or PVDF-blotted bands; free (unblocked) N-terminus required
Software Compliance	FDA 21 CFR Part 11 — audit trails, electronic signatures

Sample Requirements for Edman Sequencing

Edman degradation requires purified protein with a free (unblocked) N-terminus. The sample matrix must be free of primary amines, detergents, and other compounds that interfere with PITC coupling chemistry.

Sample Type	Minimum Amount	Purity	Preferred Buffer	Notes
Purified Protein in Solution	1–10 μg (≥10 pmol)	≥90% (≥95% recommended)	Water, 0.1% TFA, or volatile buffers	Avoid Tris, glycine, guanidine, glycerol, sucrose, SDS, Triton, Tween, ammonium salts
PVDF-Blot from SDS-PAGE	Visible Coomassie or Ponceau band (~2–10 pmol)	Single band essential	CAPS buffer for transfer; avoid Tris-glycine	Stain with Coomassie or Ponceau S only (silver stain inhibits Edman chemistry)
Synthetic Peptide	1–5 μg (≥5 pmol)	≥95%	Water or 0.1% formic acid	Free N-terminus required; specify any known modifications
Lyophilized Sample	≥20 pmol	≥75% recommended	N/A (dry)	Ship at ambient temperature in sealed container

What You Receive

Complete Edman degradation sequencing deliverables with raw chromatographic data and expert sequence interpretation.

analytics

PTH-Amino Acid Chromatograms

Cycle-by-cycle HPLC chromatograms with PTH-amino acid peak assignments, retention times, and integrated peak areas documenting each residue call.

table_chart

Sequence Assembly Table

Tabulated N-terminal sequence with per-cycle yield, retention time, and confidence scores for each identified residue.

description

Executive Summary

Methods description, complete N-terminal sequence, read-length achieved, initial and repetitive yield data, and expert interpretation with comparison to expected sequence.

folder_open

Raw Data Files

All raw HPLC chromatogram files and processed sequence data for independent review and archival documentation.

For full protein characterization, consider peptide mapping for sequence coverage confirmation and peptide testing for synthetic peptide QC.

Open analytical report showing Edman degradation results — cycle-by-cycle PTH-amino acid HPLC chromatograms and N-terminal sequence assembly with per-residue yield data.

Published Research

Novel Peptide Macoluxin from Madagascar Cat-Eyed Snake Venom Blocks Nicotinic Acetylcholine Receptor

Journal

Russ J Bioorg Chem

Year

2023

DOI

10.1134/S1068162023030159

Study Overview

Kryukova et al. (Russian Journal of Bioorganic Chemistry, 2023) screened the venom of the Madagascar cat-eyed snake (Madagascarophis colubrinus) — a rear-fanged species — and discovered macoluxin, a novel peptide that competitively inhibits muscle-type nicotinic acetylcholine receptors (nAChR). This work marked the first identification of nAChR-inhibitory activity in any rear-fanged snake species, significantly expanding the known pharmacological diversity of snake venom components. The venom was fractionated by size-exclusion chromatography (Superdex 75) followed by reversed-phase HPLC on a Jupiter C18 column, isolating a single bioactive fraction. Because macoluxin had no prior sequence entry in any database, Edman degradation was the only viable method for primary structure determination.

Key Methods

N-terminal sequencing by Edman degradation — primary structure of macoluxin determined on a Shimadzu PPSQ-33A automated protein sequencer, producing a complete N-terminal read without database support
Solid-phase peptide synthesis — macoluxin chemically synthesized to confirm the Edman-derived sequence and produce milligram quantities for biological validation
Competitive fluorescence binding assay — Alexa Fluor 488-labeled α-bungarotoxin used to measure macoluxin's affinity for nAChR on Torpedo californica electroplaque membranes
Two-electrode voltage clamp electrophysiology — Xenopus oocytes expressing muscle-type nAChR used to confirm macoluxin reversibly inhibited acetylcholine-evoked currents
Intracellular calcium imaging — genetically encoded Case12 calcium sensor expressed in Neuro2a and HEK293 cells to monitor real-time nAChR activity changes upon macoluxin treatment
[¹²⁵I]-α-bungarotoxin radioligand competition assay — confirmed competitive, reversible binding at the nAChR orthosteric site

Relevance to Edman Degradation Sequencing

This study exemplifies the irreplaceable role of Edman degradation when characterizing novel, unsequenced peptides — without a sequence database for MS/MS spectral matching, Edman degradation provided the definitive residue-by-residue N-terminal read that anchored the entire structural characterization.
The Shimadzu PPSQ-33A sequencer used in this study belongs to the same instrument family as our PPSQ-51A/53A platform, demonstrating the workflow's direct transferability to a service-level protein sequencing environment.
Edman sequencing revealed macoluxin's high sequence homology to a snake venom metalloproteinase fragment — a discovery that would have been far less certain by MS-based de novo sequencing alone, given the peptide's novelty and the absence of genomic context for this species.

$Reversed-phase HPLC chromatogram showing separation of fraction 18 from M. colubrinus venom on a Jupiter C18 column with 20-30% acetonitrile gradient over 60 min at 1 mL/min. The horizontal line indicates the active fraction containing macoluxin that was subsequently analyzed by Edman degradation.$

Fig. 1. Isolation of the active compound (macoluxin) from the venom of M. colubrinus. Fraction 18 was separated by reversed-phase HPLC on a Jupiter C18 column (4.6 × 250 mm) with a 20–30% acetonitrile gradient over 60 min at a flow rate of 1 mL/min. The horizontal line indicates the active fraction that was subsequently analyzed by N-terminal Edman degradation on a Shimadzu PPSQ-33A sequencer. (Adapted from Kryukova et al., 2023)

Key Finding

Edman degradation on the Shimadzu PPSQ-33A successfully determined the complete N-terminal sequence of macoluxin — a peptide with no prior sequence information in any public database. The Edman-derived sequence revealed that macoluxin is a proteolytic fragment of a larger snake venom metalloproteinase, demonstrating that venom protein processing can generate structurally distinct, biologically active peptides with pharmacological functions different from their parent molecules. Macoluxin competitively inhibited muscle-type nAChR with reversible kinetics, as confirmed by three orthogonal assays. Without Edman degradation, the primary structure of this novel peptide — and the mechanistic insight into its evolutionary origin — would have remained unresolved.

Publication Reference

Kryukova EV, Ivanov IA, Khochareva TA, Ziganshin RH, Starkov VG, Tsetlin VI, Utkin YN. A New Peptide from the Venom of the Madagascar Cat-Eyed Snake Madagascarophis colubrinus Blocks Nicotinic Acetylcholine Receptor. Russ J Bioorg Chem. 2023;49(3):529–537. DOI: 10.1134/S1068162023030159.

Frequently Asked Questions

What is the requirement for protein sample purity in Edman N-terminal sequencing?expand_more

Ideally, purity should be above 95%. With lower purity, multiple amino acids may elute in each cycle, making it difficult to attribute peaks to a single protein sequence. If the sample is a mixture, purify the target band by SDS-PAGE and electroblot to PVDF before submission.

Can Edman degradation distinguish leucine from isoleucine?expand_more

Yes — this is one of Edman's key advantages over mass spectrometry. PTH-leucine and PTH-isoleucine are chromatographically separable on the reversed-phase C18 HPLC column used for PTH-amino acid detection. MS typically requires specialized fragmentation (EThcD, UVPD) or ion mobility to differentiate these isobaric residues.

If a protein has two or more chains, how can N-terminal sequencing be conducted?expand_more

Separate the chains by SDS-PAGE electrophoresis, transfer to PVDF membrane using CAPS buffer (avoid Tris-glycine), stain with Coomassie or Ponceau S, and excise each band for individual sequencing. Each chain will be sequenced independently.

What kind of samples are not suitable for Edman degradation?expand_more

Samples with blocked N-termini (acetylated, pyroglutamylated, formylated) cannot be directly sequenced because the α-amino group required for PITC coupling is unavailable. De-blocking may be possible in some cases. Samples containing excessive non-standard amino acids without corresponding PTH standards are also unsuitable. For blocked N-termini, MS-based N-terminal sequencing is the recommended alternative.

How many amino acid residues can Edman degradation sequence?expand_more

Standard runs achieve 30 residues with high confidence. With optimized protein loading and clean samples, 60–70 residues can be resolved. The practical limit is determined by cumulative yield loss at each cycle — each cycle loses a small percentage of the sample to side reactions and incomplete cleavage, so signal diminishes with each successive round.

Is Edman degradation still relevant in the MS era?expand_more

Absolutely. Edman provides a direct, unambiguous chemical read that does not rely on database searching or computational inference. It is specifically referenced in ICH Q6B for biopharmaceutical identity testing, resolves Leu/Ile without advanced MS workflows, and serves as an orthogonal method that strengthens regulatory submissions when paired with MS-based characterization.